close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.600 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Reasons to Avoid OGN and 1 Stock to Buy Instead
Over the past six months, Organon’s shares (currently trading at $11.05) have posted a disappointing 11.7% loss, well below the S&P 500’s 32.7% gain. This may have investors wondering how to approach... 
Via StockStory
Topics Government Stocks World Trade
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look Ahead: Organon's Earnings Forecast
 
Via Benzinga
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a... 
Via MarketMinute
Topics Government
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
1 Surging Stock Worth Your Attention and 2 We Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Initial Public Offering
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
Why Organon (OGN) Stock Is Trading Up Today
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 2.1% in the morning session after the stock extended its positive momentum as the U.S. Food and Drug Administration (FDA) approved its two... 
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
3 Stocks Under $50 We Find Risky
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
From Organon & Co.
Via Business Wire
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 Healthcare Stock Worth Investigating and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter
Pharmaceutical company Organon (NYSE:OGN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales were flat year on year at $1.59 billion. The company expects the full year’s revenue to be... 
Via StockStory
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Via The Motley Fool
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars
Pharmaceutical company Organon (NYSE:OGN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.59 billion. The company expects the full year’s... 
Via StockStory
Organon Reports Results for the Second Quarter Ended June 30, 2025
From Organon & Co.
Via Business Wire
Organon Earnings: What To Look For From OGN
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings this Tuesday before market hours. Here’s what you need to know. 
Via StockStory
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
From Faruqi & Faruqi, LLP
Via Business Wire
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Organon &amp; Co. Sued for Securities Law Violations - Investors Should Contact Levi &amp; Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
Via TheNewswire.com
Topics Fraud Lawsuit
ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
From Organon & Co.
Via Business Wire
Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025
From Berger Montague
Via GlobeNewswire
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today